摘要
目的:研究软肝冲剂对CCl_4肝硬化大鼠p^(21)mRNA表达及细胞周期各时相DNA含量的影响,从mRNA、DNA水平探讨软肝冲剂阻止肝硬化的作用机理。方法:采用RT-PCR及流式细胞计数仪分别检测CCl_4肝硬化大鼠P^(21)mRNA表达、DNA含量。结果:软肝冲剂能降低CCl_4肝硬化大鼠p^(21)mRNA表达,与模型组比较差异有显著性意义(P<0.01),大剂量组的疗效与小剂量组比较无明显差异(P>0.05)。正常肝组织p^(21)mRNA呈相当低水平表达,其表达相对值为(0.17±0.06)U。定量DNA图像分析发现模型组中处于G1期的细胞数要明显多于其他各组(P<0.01),软肝冲剂大剂量组中处于G1期的细胞数要明显少于软肝冲剂小剂量组(P<0.01)。结论:软肝冲剂能调节p^(21)基因表达,调节细胞周期,促进肝细胞再生,抑制肝纤维化、肝硬化的形成。
Objective: To study the influence of Ruangan granule (RGG) on cirrhosis. Methods: The experimental cirrhosis in SD rats were induced by Carbon Tetrachloride (CCl4). p21 and its related mRNA expression and the content of DNA of the hepatic cells of different phases were determined by RT-PCR and flow cytometry. Results: The level of p21 mRNA expression was decreased by RGG, which compared with cirrhosis model group there was significant difference (P<0.01). The effect of large dose group was not significant distinction by comparison with the small dose group (P>0.05). The expression level of p21 mRNA in normal liver tissues was strikingly lower (0.17±0.06U). And DNA content analyzing showed that percentage of cells in G1-phase in model group was much higher than those in the other groups. Conclusion: RGG has shown definite effect on anti-hepatic fibrosis and cirrhosis. Their effect was better than Colchicines treatment group. The possible mechanism was to decrease the level of p21 mRNA and regulate the cell cycle, to protect hepatocytes, improve the function of liver and eliminate the evacator of cirrhosis.
出处
《中西医结合肝病杂志》
CAS
2003年第1期25-28,共4页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
基金
1998年度广州中医药大学中医药研究与发展总体规划课题(GHZ9804)
关键词
肝硬化
软肝冲剂
药效学
细胞周期
细胞周期调控蛋白质类
在医药疗法
TCM Science
Ruangan Granule/Pharmacodynamics
Hepatocirrhosis
Cell Cycle
Cell - Cycle Regulatory Proteins
Rats